Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bram Ramaekers

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Pharmacoeconomics|March 21, 2023
Comprehensive Review of Methods to Assess Uncertainty in Health Economic EvaluationsThomas Michael Otten, Sabine E Grimm, Bram Ramaekers, et al.
European Journal of Preventive Cardiology|April 1, 2020
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness studySvenja Petersohn, Xavier Pouwels, Bram Ramaekers, et al.
Annals of Clinical Biochemistry|June 1, 2018
Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessmentShona Lang, Nigel Armstrong, Sohan Deshpande, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 23, 2015
Cost-Effectiveness of Reduced Waiting Time for Head and Neck Cancer Patients due to a Lean Process RedesignPascale A M Simons, Bram Ramaekers, Frank Hoebers, et al.
Health Technology Assessment (Winchester, England)|March 21, 2024
Software with artificial intelligence-derived algorithms for analysing CT brain scans in people with a suspected acute stroke: a systematic review and cost-effectiveness analysisMarie Westwood, Bram Ramaekers, Sabine Grimm, et al.
Health Technology Assessment (Winchester, England)|May 16, 2014
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysisMarie Westwood, Manuela Joore, Penny Whiting, et al.
Health Technology Assessment (Winchester, England)|September 15, 2016
ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysisMarie Westwood, Bram Ramaekers, Shona Lang, et al.
Health Technology Assessment (Winchester, England)|September 1, 2018
Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysisMarie Westwood, Bram Ramaekers, Shona Lang, et al.
Critical Reviews in Oncology/Hematology|July 6, 2020
Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients - A systematic reviewMartijn Simons, Bram Ramaekers, Andrea Peeters, et al.
Pharmacoeconomics|July 8, 2022
Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology AppraisalThomas Otten, Rob Riemsma, Ben Wijnen, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Pharmacoeconomics|March 21, 2023
Comprehensive Review of Methods to Assess Uncertainty in Health Economic EvaluationsThomas Michael Otten, Sabine E Grimm, Bram Ramaekers, et al.
European Journal of Preventive Cardiology|April 1, 2020
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness studySvenja Petersohn, Xavier Pouwels, Bram Ramaekers, et al.
Annals of Clinical Biochemistry|June 1, 2018
Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessmentShona Lang, Nigel Armstrong, Sohan Deshpande, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 23, 2015
Cost-Effectiveness of Reduced Waiting Time for Head and Neck Cancer Patients due to a Lean Process RedesignPascale A M Simons, Bram Ramaekers, Frank Hoebers, et al.
Health Technology Assessment (Winchester, England)|March 21, 2024
Software with artificial intelligence-derived algorithms for analysing CT brain scans in people with a suspected acute stroke: a systematic review and cost-effectiveness analysisMarie Westwood, Bram Ramaekers, Sabine Grimm, et al.
Health Technology Assessment (Winchester, England)|May 16, 2014
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysisMarie Westwood, Manuela Joore, Penny Whiting, et al.
Health Technology Assessment (Winchester, England)|September 15, 2016
ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysisMarie Westwood, Bram Ramaekers, Shona Lang, et al.
Health Technology Assessment (Winchester, England)|September 1, 2018
Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysisMarie Westwood, Bram Ramaekers, Shona Lang, et al.
Critical Reviews in Oncology/Hematology|July 6, 2020
Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients - A systematic reviewMartijn Simons, Bram Ramaekers, Andrea Peeters, et al.
Pharmacoeconomics|July 8, 2022
Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology AppraisalThomas Otten, Rob Riemsma, Ben Wijnen, et al.
Pageof 4